Why Is MESOBLAST LTD ADR (MESO) Stock Up Today?

MESO stock is up 9.65% at $17.10 as of the latest available data, driven by the completion of patient treatment in its pivotal Phase 3 trial for chronic low back pain. The company announced it has completed enrollment in the MSB-DR004 trial, which evaluates Rexlemestrocel-L as a treatment for chronic low back pain. This marks a key milestone in the development of the drug and has generated positive market reaction.

What Happened

Mesoblast Limited (Nasdaq:MESO) announced that it has completed patient treatment in its Phase 3 trial for Rexlemestrocel-L, a cell therapy candidate for chronic low back pain. The trial, known as MSB-DR004, enrolled 350 patients and is designed to assess the safety and efficacy of the treatment. This development is a significant step forward in the company's pipeline and signals progress toward potential regulatory approval. The news was reported in multiple outlets, including The Fly and Business Insider, and was highlighted as a major milestone for the company.

What The Data Shows

The stock opened at $17.01, a 9.1% gap up from the prior close of $15.60. The session high of $17.48 was reached shortly after the market opened at 9:30 AM ET, while the session low of $16.99 occurred at the same time. Trading volume has been light so far at 0.0M shares, which is 0.2 times the 3-month daily average. The stock has printed one fresh 52-week low on August 17, 2026. The company has a market cap of $2.0B, unprofitable with a trailing twelve-month EPS of -0.07, and revenue has increased by 1053.2% over the same period.

What To Watch

The company has no scheduled earnings date in the near term. Investors will likely monitor the breadth of coverage in the coming days to assess the market's continued reaction to the trial completion.